| Aug 1 |
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
|
| Jul 11 |
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point
|
| Jul 11 |
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39%
|
| Jul 11 |
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
|
| Jul 10 |
DiaMedica Therapeutics files to sell 4.72M common shares for holders
|
| Jul 1 |
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
|
